During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment of unresectable hepatocellular carcinoma ... Biopsy was obtained and ...

and its high expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients. However, the mechanistic role of PCNA in HCC progression remains poorly understood. This study ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

The trial compared the combo against the investigator’s choice of tyrosine kinase inhibitor monotherapy in the unresectable or advanced hepatocellular carcinoma patient group. Credit: ...

In this paper, we mainly review the acquisition protocols of dynamic imaging, related kinetic parameters, advantages and the application of dynamic PET/CT imaging in malignant tumors, including lung ...

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...

Objective To characterise gut microbiome in patients with hepatocellular carcinoma (HCC) and evaluate the potential of microbiome as non-invasive biomarkers for HCC. Design We collected 486 faecal ...